Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 29 2022 - 3:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with cancer and
autoimmune diseases, today reported the grant of inducement awards
to Charlene Banard, its new Executive Vice President, Chief
Technical Officer.
The Compensation Committee of Atara’s Board of Directors granted
Ms. Banard 155,350 restricted stock units of Atara’s common stock,
time-based stock options to purchase 292,023 shares of Atara’s
common stock and performance-based stock options to purchase 33,184
shares of Atara’s common stock under the Atara Biotherapeutics,
Inc. 2018 Inducement Plan, with a grant date of April 25, 2022, as
an inducement material to the new employee entering into employment
with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to Ms. Banard being continuously
employed by Atara as of such vesting dates. The time-based stock
options vest over four years, with 25 percent vesting on the first
anniversary of the vesting commencement date and the remainder
vesting in 36 equal monthly installments over the following three
years, subject to Ms. Banard being continuously employed by Atara
as of such vesting dates. The performance-based stock options vest
upon the achievement of certain performance goals set by Atara’s
Board of Directors or the Compensation Committee of Atara’s Board
of Directors, subject to Ms. Banard being continuously employed by
Atara as of the applicable vesting date. The stock options have a
ten-year term and an exercise price of $7.29 per share, equal to
the per share closing price of Atara’s common stock as reported by
Nasdaq on April 25, 2022.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program in Phase 3 clinical development and
currently under review to support registration in Europe, Atara is
the most advanced allogeneic T-cell immunotherapy company and
intends to rapidly deliver off-the-shelf treatments to patients
with high unmet medical need. Our platform leverages the unique
biology of EBV T cells and has the capability to treat a wide range
of EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel® (tabelecleucel) in Phase 3 development
for Epstein-Barr virus-driven post-transplant lymphoproliferative
disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV
antigens as a potential treatment for multiple sclerosis; and
multiple next-generation chimeric antigen receptor T-cell (CAR-T)
immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop
working to bring transformative therapies to those in need. Atara
is headquartered in South San Francisco and our leading-edge
research, development and manufacturing facility is based in
Thousand Oaks, California. For additional information about the
company, please visit atarabio.com and follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220429005657/en/
Investors Eric Hyllengren 805-395-9669
ehyllengren@atarabio.com Media Alex Chapman 805-456-4772
achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024